הכנסה לפני ניכוי ריבית, מסים ופחת: Intra-Cellular Therapies (ITCI)

The growth of Intra-Cellular Therapies (ITCI) relies on the demand for Caplyta and the expansion of insurance coverage limits. Experienced management is effectively scaling sales by leveraging market confidence. This chart of cash operating profit before deductions demonstrates liquidity dynamics, where the mark indicates the efficiency level. Revenues are generated through the treatment of patients with schizophrenia and bipolar disorder in specialized clinics.

This indicator measures the business's ability to generate cash flow from core operations before deducting depreciation and interest, reflecting the actual efficiency of the operating cycle. By analyzing the monthly EBITDA trend, an investor can assess the dependence of Intra-Cellular Therapies (ITCI) on Caplyta sales, where any decline in profit signals regulatory pressure or patent risks, warning against the purchase of an overvalued asset.